Kymera Therapeutics KYMR
$115.31 −$4.08 (-3.42%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $124.06 +7.59%
Open$117.89
Prev close$119.39
Day range$114.40 – $119.60
Volume1.28M
Market cap$9.84B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00-100.0% YoY
Operating profit-$147.23M-66.1% YoY
Net profit-$132.00M-60.6% YoY
Diluted EPS-$1.32-40.4% YoY
Free cash flow-$78.23M-186.6% YoY
Operating cash flow-$77.91M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Operating margin-396.0%
Net margin-341.8%
Return on equity-27.3%
Return on assets-24.4%
Return on invested capital-29.8%
Current ratio11.13
Liabilities / assets8.6%
Cash & investments$971.21M
Total debt$63.02M
Net cash (debt)$908.20M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $0.00 | $65.00M | $34.37M | $39.21M | $2.87M |
| Total Operating Revenue | $0.00 | $65.00M | $34.37M | $39.21M | $2.87M |
| Operating Expense | $147.23M | $140.61M | $118.52M | $384.76M | $100.77M |
| Selling and Admin Expenses | $18.72M | $21.13M | $20.36M | $68.19M | $16.94M |
| -General & Admin Expense | $18.72M | $21.13M | $20.36M | $68.19M | $16.94M |
| Research & Development | $128.51M | $119.48M | $98.16M | $316.57M | $83.83M |
| Operating Profit | -$147.23M | -$75.61M | -$84.15M | -$345.54M | -$97.90M |
| Net Non-Operating Interest Income (Expense) | $15.23M | $14.40M | $14.92M | $38.05M | $10.92M |
| Non-Operating Interest Income | $15.30M | $14.48M | $14.98M | $38.42M | $11.01M |
| Non-Operating Interest Expense | $62,000.00 | $81,000.00 | $61,000.00 | $370,000.00 | $90,000.00 |
| Special Income (Charges) | $0.00 | – | – | -$3.86M | $0.00 |
| -Less:Impairment of Capital Assets | $0.00 | – | – | $3.86M | $0.00 |
| Pretax Profit | -$132.00M | -$61.21M | -$69.23M | -$311.35M | -$86.98M |
| Net Profit | -$132.00M | -$61.21M | -$69.23M | -$311.35M | -$86.98M |
| Profit from Continuing Operations | -$132.00M | -$61.21M | -$69.23M | -$311.35M | -$86.98M |
| Net Income to Parent Company | -$132.00M | -$61.21M | -$69.23M | -$311.35M | -$86.98M |
| Net Income to Common Stockholders | -$132.00M | -$61.21M | -$69.23M | -$311.35M | -$86.98M |
| Basic EPS | -$1.32 | -$0.62 | -$0.71 | -$3.69 | -$0.97 |
| Diluted EPS | -$1.32 | -$0.62 | -$0.71 | -$3.69 | -$0.97 |
| Other Income (Expense) | – | – | – | -$3.86M | $0.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $1.77B | $1.65B | $1.67B | $1.74B | $1.74B |
| Total Current Assets | $998.59M | $737.27M | $677.43M | $871.21M | $871.21M |
| Cash and Cash Equivalents & Short-Term Investments | $971.21M | $690.99M | $650.93M | $848.28M | $848.28M |
| -Cash and Cash Equivalents | $373.37M | $124.48M | $144.09M | $357.01M | $357.01M |
| -Short Term Investments | $597.84M | $566.51M | $506.84M | $491.27M | $491.27M |
| Other Current Assets | $27.38M | $26.28M | $26.50M | $22.94M | $22.94M |
| Total Non-Current Assets | $768.68M | $908.18M | $991.58M | $871.60M | $871.60M |
| Net PPE | $78.69M | $81.07M | $83.35M | $85.53M | $85.53M |
| -Gross PPE | $106.80M | $107.16M | $107.41M | $107.65M | $107.65M |
| -Accumulated Depreciation | -$28.11M | -$26.09M | -$24.06M | -$22.13M | -$22.13M |
| Investments and Advances | $674.67M | $813.90M | $894.72M | $771.16M | $771.16M |
| -Available for Sale Securities | $674.67M | $813.90M | $894.72M | $771.16M | $771.16M |
| Other Non-Current Assets | $15.32M | $13.21M | $13.51M | $14.91M | $14.91M |
| Total Liabilities | $152.74M | $136.19M | $129.38M | $163.15M | $163.15M |
| Total Current Liabilities | $89.72M | $71.33M | $62.64M | $83.21M | $83.21M |
| Payables | $11.92M | $8.92M | $12.84M | $4.02M | $4.02M |
| -Accounts Payable | $11.92M | $8.92M | $12.84M | $4.02M | $4.02M |
| Current Accrued Expenses | $63.32M | $48.48M | $35.10M | $42.27M | $42.27M |
| Short-Term Debt and Capital Lease Obligation | $13.58M | $13.70M | $13.73M | $13.76M | $13.76M |
| -Current Capital Lease Obligation | $13.58M | $13.70M | $13.73M | $13.76M | $13.76M |
| Current Deferred Liabilities | $0.00 | $0.00 | $0.00 | $22.93M | $22.93M |
| Other Current Liabilities | $905,000.00 | $236,000.00 | $976,000.00 | $242,000.00 | $242,000.00 |
| Total Non-Current Liabilities | $63.02M | $64.86M | $66.74M | $79.94M | $79.94M |
| Long Term Debt and Capital Lease Obligation | $63.02M | $64.86M | $66.74M | $68.50M | $68.50M |
| -Long Term Capital Lease Obligation | $63.02M | $64.86M | $66.74M | $68.50M | $68.50M |
| Non-Current Deferred Liabilities | $0.00 | $0.00 | $0.00 | $11.44M | $11.44M |
| Total Equity | $1.61B | $1.51B | $1.54B | $1.58B | $1.58B |
| Stockholders' Equity | $1.61B | $1.51B | $1.54B | $1.58B | $1.58B |
| Capital Stock | $9,000.00 | $8,000.00 | $8,000.00 | $8,000.00 | $8,000.00 |
| -Common Stock | $9,000.00 | $8,000.00 | $8,000.00 | $8,000.00 | $8,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $2.96B | $2.71B | $2.68B | $2.64B | $2.64B |
| Retained Earnings | -$1.33B | -$1.20B | -$1.14B | -$1.07B | -$1.07B |
| Gains/Losses Not Affecting Retained Earnings | -$14.74M | -$7.16M | -$4.19M | $1.80M | $1.80M |
| Receivables | – | $20.00M | – | – | – |
| -Accounts Receivable | – | $20.00M | – | – | – |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$77.91M | -$54.07M | -$88.84M | -$232.89M | -$66.75M |
| Net cash flow from continuing operations | -$77.91M | -$54.07M | -$88.84M | -$232.89M | -$66.75M |
| Net Income from Continuing Operations | -$132.00M | -$61.21M | -$69.23M | -$311.35M | -$86.98M |
| Depreciation & Depletion & Amortization | $2.02M | $2.03M | $2.02M | $8.31M | $2.03M |
| Change in Working Capital | $34.83M | -$11.50M | -$34.91M | $15.27M | $5.79M |
| -Change in Receivables | $20.00M | -$20.00M | $0.00 | $947,000.00 | $0.00 |
| -Change in Prepaid Assets | -$1.10M | $223,000.00 | -$3.57M | -$2.36M | -$322,000.00 |
| -Change in Payables and Accrued Expense | $17.86M | $9.55M | $1.62M | $5.41M | $12.17M |
| -Change in Other Current Assets | -$1.07M | $2.37M | $615,000.00 | $2.67M | $5.47M |
| -Change in Other Current Liabilities | -$1.52M | -$1.48M | -$1.36M | -$5.04M | -$1.33M |
| -Change In Other Working Capital | $654,000.00 | -$2.16M | -$32.21M | $13.64M | -$10.20M |
| Net cash flow from investing | $101.63M | $20.05M | -$142.84M | -$521.06M | -$394.40M |
| Net Cash Flow from Continuing Investing Activities | $101.63M | $20.05M | -$142.84M | -$521.06M | -$394.40M |
| Net PPE Purchase and Sale | -$315,000.00 | -$473,000.00 | -$434,000.00 | -$1.45M | -$106,000.00 |
| Net Investment Purchase and Sale | $101.95M | $20.52M | -$142.41M | -$519.61M | -$394.29M |
| Financing Cash Flow | $225.57M | $14.42M | $18.77M | $990.71M | $705.22M |
| Net Cash Flow from Continuing Financing Activities | $225.57M | $14.42M | $18.77M | $990.71M | $705.22M |
| Net Issuance Payments Of Debt | -$444,000.00 | -$436,000.00 | -$425,000.00 | -$1.49M | -$416,000.00 |
| Net Common Stock Issuance | $215.39M | – | – | $928.90M | $656.23M |
| Proceeds from Stock Option Exercised | $10.62M | $14.86M | $19.19M | $63.31M | $49.41M |
| Ending Cash Balance | $379.58M | $130.30M | $149.90M | $362.81M | $362.81M |
| Net Change in Cash | $249.28M | -$19.60M | -$212.91M | $236.76M | $244.07M |
| Beginning Cash Balance | $130.30M | $149.90M | $362.81M | $126.05M | $118.74M |
| Free Cash Flow | -$78.23M | -$54.54M | -$89.27M | -$234.34M | -$66.85M |
| Gain/Loss from Continuing Operations | – | – | -$2.73M | – | – |
No comments yet — be the first to weigh in on KYMR.
Sign in to join the discussion.